Huajin Sinogen Announces Appointment of Christie Chiu as Global Director of Clinical Operations

October 18, 2021, Guangzhou, China-Guangzhou Huajin Pharmaceutical Technology Co., Ltd. ("Huajin Pharmaceutical") is pleased to announce today the appointment of Christie Chiu (Qiu Jiahui) as the company's global clinical operations director. Ms. Christie Chiu will be responsible for the global clinical operations of the company's products, with a focus on the management of the SGN1 clinical trial in the United States and Taiwan. Huajin Pharmaceutical is an original new drug research and development enterprise that has entered the clinical stage. It is committed to the development of innovative biological anti-tumor drugs to meet the global market demand for malignant tumor treatment.

Christie Chiu

Christie Chiu graduated from the School of Public Health of Taiwan University with a master's degree in epidemiology. She has more than 21 years of experience in clinical trial development, more than 10 years of experience in team management and cross-department integrated management. She has worked in well-known CRO companies at home and abroad, such as International Jingding (Parexel APEX), i3 Research and Fang En Medicine (FMD), and CRA (certified CRA qualification, CCRA) certified by ACRP, International Clinical Research Association, have comprehensive experience in managing international multi-center pivotal clinical trials. As manager of the global project, we have led a number of phase III clinical trials in Asian countries, involving oncology (HCC, NSCLC, FLL, ovarian cancer, etc.), infectious diseases (HBV & HCV) and other fields.

Huajin Pharmaceuticals, said, "Christie has extensive experience in global clinical operation and management of new drugs, especially in the clinical field of oncology drugs. Her joining will play an important role in promoting the clinical trials of our product pipeline in the United States and in China in the future. We are very much looking forward to Christie with the Huajin clinical consultant and operation team composed of academician Zhang Dan and other industry veterans to seek the future and create better results."